Dainippon Sumitomo Pharma Co. Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Dainippon Sumitomo in the Rx pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Report Highlights

[Studien Infos ausblenden]

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
DSP: PharmaVitae forecasts at a glance 7
Strategic insight 8
2005 marked a pivotal year for the company 8
Increasingly competitive Japanese market 9
Options available to reduce risk of strategic plans 11
SWOT analysis 14
Strengths 14
Weaknesses 15
Opportunities 16
Threats 18
CHAPTER 3 QUARTERLY NEWS UPDATE 22
Product developments 22
Deals and alliances 23
Product deals 23
Technology deals 23
M&A activity 24
Company announcements 24
Future product milestones 24
CHAPTER 4 COMPANY INTRODUCTION 25
Key findings 25
Background 26
Key corporate developments 26
M&A history 27
Osaka Pharmaceuticals Co. Ltd. acquires Dainippon Pharmaceuticals Company 27
Sumitomo Chemical Company established 28
Divestment of OTC franchises. 28
Merger of Dainippon and Sumitomo 28
M&A strategy 28
Strengthened portfolio 29
Geographic expansion 29
Current corporate structure 30
Pharmaceuticals unit 30
Animal science unit 30
Food science unit 31
Fine chemicals unit 31
Laboratory products unit 31
CHAPTER 5 COMPANY SALES 33
Prescription pharmaceutical sales and growth rate analysis, 2001-13 33
Product analysis 36
Product analysis, 2001-07 36
Product analysis, 2007-13 39
Therapy area analysis 42
Therapy area analysis, 2001-07 43
Therapy area analysis, 2007-13 45
Therapy area focus, 2001-13 47
Geographic analysis 48
Geographic analysis, 2001-07 49
Geographic analysis, 2007-13 51
Geographic focus, 2001-13 53
Launch/core/expiry analysis 54
Explanation of launch/core/expiry analysis 54
Launch analysis, 2007-13 55
Core analysis, 2007-13 56
Expiry analysis, 2007-13 57
Launch/core/expiry configuration, 2007-13 58
Molecule type analysis 59
Molecule type analysis, 2001-07 60
Molecule type analysis, 2007-13 61
Externalization analysis 63
Externalization analysis, 2001-07 64
Externalization analysis, 2007-13 65
CHAPTER 6 COMPANY FINANCIALS 67
Key findings 67
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 68
Financial statements, 2001-07 70
Profit and loss account, 2001-07 70
Balance sheet, 2001-07 72
Operating costs and profit analysis 74
Operating costs and profit analysis, 2001-07 75
Operating cost ratio and profit margin analysis, 2001-07 76
Operating cost ratio and profit margin analysis, 2007-13 79
Operating costs and profit analysis, 2007-13 82
Return on capital employed analysis 84
Capital employed analysis, 2001-07 85
Return on capital employed (RoCE) analysis, 2001-07 87
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 91
Cardiovascular 91
Amlodin 91
Overview 91
Sales forecast 92
Prorenal 94
Overview 94
Sales forecast 95
CHAPTER 8 APPENDIX 96
R&D pipeline 96
References 97
Abbreviations 97
Exchange rates 98
[Inhaltsverzeichnis ausblenden]

Table 1: DSP - PharmaVitae forecasts at a glance 7
Table 2: DSP key product developments, 2008 22
Table 3: DSP product deals and alliances, Q1 2008 23
Table 4: DSP technology deals and alliances, 2008 23
Table 5: DSP M&A activity, 2008 24
Table 6: DSP company announcements, 2008 24
Table 7: DSP future product milestones, 2008-10 24
Table 8: DSP product portfolio overview ($m), 2001-07 36
Table 9: DSP product portfolio overview ($m), 2007-13 39
Table 10: DSP product portfolio overview ($m), 2001-07 43
Table 11: DSP product portfolio overview ($m), 2007-13 45
Table 12: DSP portfolio overview by geographic region ($m), 2001-07 49
Table 13: DSP portfolio overview by geographic region ($m), 2007-13 51
Table 14: DSP launch portfolio overview ($m), 2007-13 55
Table 15: DSP core portfolio overview ($m), 2007-13 56
Table 16: DSP expiry portfolio overview ($m), 2007-13 57
Table 17: DSP portfolio overview by molecule type ($m), 2001-07 60
Table 18: DSP product portfolio overview ($m), 2007-13 61
Table 19: DSP product portfolio overview by source ($m), 2001-07 64
Table 20: DSP product portfolio overview by source ($m), 2007-13 65
Table 21: Total DSP sales by business unit ($m), 2001-07 68
Table 22: DSP profit and loss account ($m), 2001-07 70
Table 23: DSP balance sheet ($m), 2001-07 72
Table 24: DSP operating revenue/cost analysis ($m), 2001-07 75
Table 25: DSP operating cost ratio analysis (% of total revenues), 2001-07 76
Table 26: DSP operating cost ratio analysis (% of total revenues), 2007-13 79
Table 27: DSP operating revenue/cost analysis ($m), 2007-13 82
Table 28: DSP capital employed ($m), 2001-07 85
Table 29: DSP EBIT return on capital employed ($m), 2001-07 87
Table 30: DSP EBIT pre-tax return/Capital employed driver analysis (%), 2001-07 88
Table 31: Amlodin: overview 91
Table 32: Amlodin: sales forecast ($m), 2007-13 92
Table 33: Prorenal: overview 94
Table 34: Prorenal: sales forecast ($m), 2007-13 95
Table 35: DSP's R&D pipeline (Phase I-registration) 96
Table 36: Exchange rates, 2007 98
Figure 1: DSP prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: DSP financial performance ($m), 2001-13 6
Figure 3: DSP prescription pharmaceutical sales, split by pre-merger company, 2001-07 ($m) 8
Figure 4: Generic drug penetration rates in different markets, 2003-07 (% volume) 10
Figure 5: Outlook for DSP, mid-term business plan 11
Figure 6: DSP SWOT analysis 14
Figure 7: M&A/divestment history 27
Figure 8: DSP, current corporate structure 30
Figure 9: DSP prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 33
Figure 10: DSP key sales growth driverss& resistors ($m), 2001-07 37
Figure 11: DSP key sales growth drivers & resistors ($m), 2007-13 40
Figure 12: DSP prescription pharmaceutical sales by therapy area ($m), 2001-13 42
Figure 13: DSP prescription pharmaceutical sales by therapy area ($m), 2006 44
Figure 14: DSP prescription pharma sales by therapy area (% of total), 2001-13 47
Figure 15: DSP prescription pharmaceutical sales by geographic region ($m), 2001-13 48
Figure 16: DSP growth drivers and resistors by geographic region ($m), 2001-07 49
Figure 17: DSP drivers and resistors by geographic region ($m), 2007-13 51
Figure 18: DSP prescription pharmaceutical sales by geographic region (% of total), 2001-13 53
Figure 19: DSP launch/core/expiry configuration ($m), 2007-13 58
Figure 20: DSP prescription pharmaceutical sales by molecule type ($m), 2001-13 59
Figure 21: DSP growth drivers and resistors by molecule type ($m), 2007-13 62
Figure 22: DSP prescription pharmaceutical sales by source ($m), 2001-13 63
Figure 23: DSP growth drivers and resistors by source ($m), 2001-07 64
Figure 24: DSP growth drivers and resistors by source ($m), 2007-13 66
Figure 25: DSP operating revenue/cost analysis ($m), 2001-13 74
Figure 26: DSP gross margin analysis, quarterly 2005-06 78
Figure 27: DSP operating cost ratio analysis (% of total revenues), 2001-13 81
Figure 28: DSP return on capital employed, EBIT margin and capital turnover, 2001-07 84
Figure 29: Return on capital employed formula 89
[Tabellenverzeichnis ausblenden]